

Comment on ‘Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy’

Letter to the Editor

Cite this article: Topkan E, Somay E, Ozturk D, and Selek U (2025) Comment on ‘Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy’. *British Journal of Nutrition* **133**: 211–212. doi: [10.1017/S0007114524003039](https://doi.org/10.1017/S0007114524003039)

Received: 11 October 2024

Accepted: 20 November 2024

First published online: 20 December 2024

Keywords:

Sarcopenia; Myopenia; Dynapenia; Head and neck cancer; Weight loss

Abbreviations:

CWL, critical weight loss; SO, sarcopenic obesity

Corresponding author:

Efsun Somay; Email: efsuner@gmail.com

Erkan Topkan¹, Efsun Somay² , Duriye Ozturk³ and Ugur Selek⁴

¹Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey; ²Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey; ³Department of Radiation Oncology, Afyonkarahisar Health and Science University, Afyonkarahisar, Turkey and ⁴Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey

Dear Editor,

We congratulate Vangelov and colleagues for their study, which primarily examined sarcopenic obesity (SO) prevalence and its influence on survival of 413 head and neck cancer patients treated with curative intent. SO was defined utilising BMI and radiologically defined sarcopenia status⁽¹⁾. The secondary objective of this study was to identify the predictors of critical weight loss (CWL) concerning SO within this patient cohort. CWL, sarcopenia and SO were identified in 58 %, 43 % and 28 % of the study population. Patients with SO were found to have a significantly higher incidence of CWL (70 v. 19, $P < 0.001$) and were fourfold increase in this condition during treatment (OR 4.1; $P = 0.002$). Study results revealed that sarcopenia did not impact overall survival or cancer-specific survival. However, in the sarcopenia group, those with SO had better overall survival (median 9.1 v. 7.0 years; $P = 0.021$). The authors should address two critical issues to improve our understanding of the results presented and provide a solid foundation for future research projects.

First, the authors indicated that individuals with SO exhibited a markedly elevated incidence of CWL (70 v. 19, $P < 0.001$) and were four times more likely to encounter this condition during therapy (OR 4.1; $P = 0.002$) compared to non-SO patients. However, their comparison methodology is not statistically sound⁽²⁾. This is because the comparisons between the absolute numbers of events in different groups may only indicate meaning if converted to the relative percentages per group. To illustrate, 70/116 (60.3 %) SO patients and 19/297 (6.4 %) non-SO patients experienced CWL before the intended treatment, and the discrepancy between the two groups is more pronounced when comparing the percentages than merely comparing the absolute numbers of CWL in each group. Additionally, in the original Table 1 of the manuscript, the authors did not include the relative distributions of the baseline patient, disease and treatment characteristics and the corresponding P -values, which is indispensable for a thorough comparison between the two groups⁽³⁾. However, some factors may unintentionally favor one group over another, potentially impacting the presented results. For example, N1–3 status was evident in 70/116 (60 %) SO patients and 211/297 (71 %) non-SO patients, which may have offset the survival benefit of the non-SO status.

And second, considering the European Working Group on Sarcopenia in Older People (EWGSOP1 and EWGSOP2) definitions for sarcopenia, in their study^(4,5), Vangelov and colleagues define myopenia rather than sarcopenia⁽¹⁾. Accordingly, an accurate diagnosis of sarcopenia necessitates the identification of dynapenia (loss of muscle strength) as the primary criterion, with myopenia (reduction in muscle mass) serving as the confirmatory criterion⁽⁵⁾. Therefore, assessing muscle mass alone using radiological tools to measure skeletal muscle index in cancer patients does not meet the comprehensive criteria for diagnosing sarcopenia^(4,5). Although this erroneous terminology is frequently utilised in the sarcopenia literature^(6,7), in studies that lack muscle strength evaluations, it is prudent to use ‘myopenia’ term rather than ‘sarcopenia’ so as not to underestimate the actual incidence and prognostic impact of sarcopenia in cancer patients, including those with head and neck cancer.

Acknowledgements. No financial support provided.

All authors have viewed and agreed to the submission.

There are no conflicts of interest.

References

1. Vangelov B, Smee RI & Bauer J (2024) Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy. *Br J Nutr* **132**(5), 599–606.
2. Nayak BK & Hazra A (2011) How to choose the right statistical test? *Indian J Ophthalmol* **59**, 85–86.
3. Hazra A & Gogtay N (2016) Biostatistics series module 4: comparing groups – categorical variables. *Indian J Dermatol* **61**, 385–392.
4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, *et al.* (2010) European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **39**, 412–423.
5. Cruz-Jentoft AJ, Bahat G, Bauer J, *et al.* (2019) Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31.
6. Takenaka Y, Takemoto N, Oya R, *et al.* (2021) Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: a meta-analysis. *PLoS One* **16**, e0259288.
7. Graves JP, Daher GS, Bauman MMJ, *et al.* (2023) Association of sarcopenia with oncologic outcomes of primary treatment among patients with oral cavity cancer: a systematic review and meta-analysis. *Oral Oncol* **147**, 106608.